Prestige BioPharma Limited (KRX:950210)

Prestige BioPharma Revenue

Prestige BioPharma had revenue of 509.20M KRW in the quarter ending March 31, 2026, a decrease of -84.75%. This brings the company's revenue in the last twelve months to 16.21B, up 87.13% year-over-year. In the fiscal year ending June 30, 2025, Prestige BioPharma had annual revenue of 14.33B with 1,978.97% growth.

• Revenue (ttm): 16.21B
• Revenue Growth: +87.13%
• P/S Ratio: 4.89
• Revenue / Employee: n/a
• Employees: 65
• Market Cap: 79.21B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2025	14.33B	13.64B	1,978.97%
Jun 30, 2024	689.08M	527.23M	325.77%
Jun 30, 2023	161.84M	-	-
Jun 30, 2022	-	-	-
Jun 30, 2021	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 19, 2026

Data Sources Report a data error